B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+5.48%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.53B
AUM Growth
+$340M
(+11%)
Cap. Flow
-$901M
Cap. Flow
% of AUM
-25.54%
Top 10 Holdings %
Top 10 Hldgs %
34.64%
Holding
89
New
15
Increased
24
Reduced
22
Closed
8
Avg Time Held
0.8
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apellis Pharmaceuticals
APLS
|
+$93.1M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$47M |
| 3 |
Bicara Therapeutics
BCAX
|
+$42.3M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$39.9M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exact Sciences
EXAS
|
+$48.3M |
| 2 |
Vaxcyte
PCVX
|
+$46M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$39M |
| 4 |
Apogee Therapeutics
APGE
|
+$35.9M |
| 5 |
argenx
ARGX
|
+$35.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.68% |
| 2 | Miscellaneous | 34.16% |
| 3 | Consumer Staples | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
DELISTED
NEVRO CORP.
NVRO
| $9.5M | 0.27% |
1,698,768
| – | – |
2022 Q4
7 quarters
|
|
52
Castle Biosciences
CSTL
$1.01B
| $9.47M | 0.27% |
331,986
-84,114
| -20% | -$2.14M |
2024 Q2
1 quarter
|
|
53
Xencor
XNCR
$1.74B
| $9.38M | 0.27% |
+466,448
| New | +$8.76M |
2024 Q3
0 quarters
|
|
54
Jasper Therapeutics
JSPR
$16.7M
| $9.09M | 0.26% |
+483,300
| New | +$9.62M |
2024 Q3
0 quarters
|
|
55
BridgeBio Pharma
BBIO
$12.7B
| $7.6M | 0.22% |
298,400
-47,171
| -14% | -$1.24M |
2024 Q1
2 quarters
|
|
56
Lexeo Therapeutics
LXEO
$216M
| $6.59M | 0.19% |
728,777
-653,704
| -47% | -$7.8M |
2024 Q1
2 quarters
|
|
57
Pulmonx
LUNG
$76.4M
| $6.24M | 0.18% |
752,541
| – | – |
2022 Q4
7 quarters
|
|
58
SkinHealth Systems
SKIN
$75.2M
| $5.83M | 0.17% |
202,485
-53,549
| -21% | -$1.76M |
2024 Q2
1 quarter
|
|
59
Fulcrum Therapeutics
FULC
$280M
| $3.82M | 0.11% |
+1,069,158
| New | +$7.93M |
2024 Q3
0 quarters
|
|
60
DELISTED
Verve Therapeutics
VERV
| $3.02M | 0.09% |
+623,980
| New | +$3.62M |
2024 Q3
0 quarters
|
|
61
Iovance Biotherapeutics
IOVA
$6.44B
| $2.05M | 0.06% |
217,928
-1,248,682
| -85% | -$11.8M |
2024 Q1
2 quarters
|
|
62
DELISTED
HilleVax
HLVX
| $1.87M | 0.05% |
+1,064,000
| New | +$2.73M |
2024 Q3
0 quarters
|
|
63
Lexicon Pharmaceuticals
LXRX
$712M
| $1.26M | 0.04% |
801,584
-7,493,366
| -90% | -$13.3M |
2024 Q2
1 quarter
|
|
64
DBV Technologies S.A. American Depositary Shares
DBVT
$557M
| $1.14M | 0.03% |
326,108
-162,393
| -33% | -$687K |
2022 Q4
7 quarters
|
|
65
DELISTED
Elevation Oncology
ELEV
| $284K | 0.01% |
473,503
-2,004,111
| -81% | -$2.97M |
2024 Q1
2 quarters
|
|
66
DELISTED
Akero Therapeutics
AKRO
| – | – |
-1,084,400
| Closed | -$25.4M | – |
|
67
DELISTED
89bio
ETNB
| – | – |
-164,227
| Closed | -$1.32M | – |
|
68
Immunocore
IMCR
$1.46B
| – | – |
-797,268
| Closed | -$27M | – |
|
69
LivaNova
LIVN
$4.19B
| – | – |
-173,900
| Closed | -$9.53M | – |
|
70
Outset Medical
OM
$72.2M
| – | – |
-46,302
| Closed | -$2.67M | – |
|
71
Transmedics
TMDX
$2.62B
| – | – |
-189,960
| Closed | -$28.6M | – |
|
|
72
Thermo Fisher Scientific
TMO
$249B
| – | – |
-70,449
| Closed | -$39M | – |
|
73
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – |
-205,926
| Closed | -$5.57M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q3 2024 Portfolio in Review
As of Q3 2024, Braidwell held 89 positions worth $3.53B, up 11% from $3.19B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Braidwell withdrew a net $901M in Q3 2024, closing 8 positions and reducing 22 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 61% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Braidwell opened a new position in Madrigal Pharmaceuticals worth $39M.
- Braidwell's largest Q3 2024 buy was Madrigal Pharmaceuticals: 183,818 shares worth $39M.
- Braidwell added most to Apellis Pharmaceuticals in Q3 2024, an estimated $93.1M increase.
- Braidwell's biggest Q3 2024 reduction was Exact Sciences, cutting an estimated $48.3M.
- Braidwell fully exited Thermo Fisher Scientific in Q3 2024, selling an estimated $39M.
- Braidwell's ten largest holdings make up 35% of its $3.53B portfolio in Q3 2024.
- Braidwell opened 15 new positions and closed 8 in Q3 2024.
- Braidwell's portfolio value rose 11% quarter-over-quarter to $3.53B.
Based on Braidwell's 13F filing for Q3 2024, filed 14 Nov 2024.